DNMT1 and colorectal carcinoma: Understanding DNA methylation status aids in predicting CRC treatment outcomes, addressing chemoresistance challenges, and exploring therapeutic interventions such as DNMT inhibitors for patients with CRC, emphasizing the relevance of epigenetic compositions in therapy response variations among individuals.